Dicerna Pharma (DRNA) Misses Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Francisco Partners to acquire Weave Communications for $650M
B.Riley/FBR Upgrades Dicerna Pharmaceuticals (DRNA) to Buy
November 6, 2018 3:36 AM ESTB.Riley/FBR analyst Madhu Kumar upgraded Dicerna Pharmaceuticals (NASDAQ: DRNA) from Neutral to Buy with a price target of $21.00 (from $13.50).
For an analyst ratings summary and ratings history on Dicerna Pharmaceuticals click here. For more ratings news on Dicerna Pharmaceuticals click here.
Shares of Dicerna Pharmaceuticals closed at $12.94 yesterday.
... More